Novartis Faces Setbacks in Heart Drug Trial Amid Financial Outlook Questions

Novartis encountered difficulties in a clinical trial for a cardiovascular medication, prompting investor scrutiny over the pharmaceutical giant’s near-term prospects. Analysts are now weighing whether progress in its rare-disease portfolio can offset the setback.